Chemotherapy for advanced prostate cancer: 25 Years later

Journal of Clinical Oncology

Volumn 26, Issue 15, 2008, Pages 2423-2424

  Logothetis, Christopher J ^a   Millikan, Randall ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIANDROGEN; DOCETAXEL; DOXORUBICIN; FLUOROURACIL; MITOMYCIN C; PROSTATE SPECIFIC ANTIGEN; ANTINEOPLASTIC AGENT;

ASTHENIA; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER PAIN; CANCER PATIENT; CANCER SURGERY; CANCER SURVIVAL; CASTRATED MALE; CLINICAL DECISION MAKING; CLINICAL TRIAL; DRUG EFFICACY; HUMAN; NOTE; PRIORITY JOURNAL; PROSTATE CANCER; SOLID TUMOR; TUMOR REGRESSION; UNSPECIFIED SIDE EFFECT; VISCERAL METASTASIS; MALE; PROSTATE TUMOR; TIME;

ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; HUMANS; MALE; PROSTATIC NEOPLASMS; TIME FACTORS;

EID: 45149115061     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2007.14.7819     Document Type: Note

References (19)

1. Logothetis CJ, Samuels ML, von Eschenbach AC, et al: Doxorubicin, mitomycin-C, and 5-fluorouracil (DMF) in the treatment of metastatic hormonal refractory adenocarcinoma of the prostate, with a note on the staging of metastatic prostate cancer. J Clin Oncol 1:368-379, 1983
2. Slack NH, Murphy GP: A decade of experience with chemotherapy for prostate cancer. Urology 22:1-7, 1983
3. Tannock IF, Osoba D, Stockler MR, et al: Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: A Canadian randomized trial with palliative end points. J Clin Oncol 14:1756-1764, 1996
4. Petrylak DP, Tangen CM, Hussain MH, et al: Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 351:1513-1520, 2004
5. Tannock IF, de Wit R, Berry WR, et al: Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351:1502-1512, 2004
6. Murphy GP, Beckley S, Brady MF, et al: Treatment of newly diagnosed metastatic prostate cancer patients with chemotherapy agents in combination with hormones versus hormones alone. Cancer 51:1264-1272, 1983
7. Murphy GP, Huben RP, Priore R: Results of another trial of chemotherapy with and without hormones in patients with newly diagnosed metastatic prostate cancer. Urology 28:36-40, 1986
8. Osborne CK, Blumenstein B, Crawford ED, et al: Combined versus sequential chemo-endocrine therapy in advanced prostate cancer: Final results of a randomized Southwest Oncology Group study. J Clin Oncol 8:1675-1682, 1990
9. Pummer K, Lehnert M, Stettner H, et al: Randomized comparison of total androgen blockade alone versus combined with weekly epirubicin in advanced prostate cancer. Eur Urol 32:81-85, 1997 (suppl)
10. Fontana D, Bertetto O, Fasolis G, et al: Randomized comparison of goserelin acetate versus mitomycin C plus goserelin acetate in previously untreated prostate cancer patients with bone metastases. Tumori 84:39-44, 1998
11. Pettaway CA, Pisters LL, Troncoso P, et al: Neoadjuvant chemotherapy and hormonal therapy followed by radical prostatectomy: Feasibility and preliminary results. J Clin Oncol 18:1050-1057, 2000
12. Chung LWK, Li W, Gleave ME, et al: Human prostate cancer model: Roles of growth factors and extracellular matrices. J Cell Biochem Suppl 16H:99-105, 1992
13. McDonnell TJ, Troncoso P, Brisbay SM, et al: Expression of the proto-oncogene bcl-2 in the prostate and its association with the emergence of androgen-independent prostate cancer. Cancer Res 52:6940-6944, 1992
14. Hoosein N, Abdul M, and Logothetis CJ: Significance of neuroendocrine differentiation in prostatic carcinoma. The Cancer Journal 9:291-295, 1996
15. Papandreou CN, Daliani DD, Thall PF, et al: Results of a phase II study with doxorubicin, etoposide, and cisplatin in patients with fully characterized small-cell carcinoma of the prostate. J Clin Oncol 20:3072-3080, 2002
16. Tu SM, Millikan RE, Mengistu B, et al: Bone-targeted therapy for advanced androgen-independent carcinoma of the prostate: A randomized phase II trial. The Lancet 357:336-341, 2001
17. Mathew P, Thall PF, Bucana CD, et al: Platelet-derived growth factor receptor inhibition and chemotherapy for castration-resistant prostate cancer with bone metastases. Clin Cancer Res 13:5816-5824, 2007
18. Assikis VJ, Do KA, Wen S, et al: Clinical and biomarker correlates of androgen-independent, locally aggressive prostate cancer with limited metastatic potential. Clin Cancer Res 10:6770-6778, 2004
19. Bolla M, Gonzalez D, Warde P, et al: Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N Engl J Med 337:295-300, 1997